Siver Andreas Moestue
Førsteamanuensis Institutt for sirkulasjon og bildediagnostikk Institutt for laboratoriemedisin, barne- og kvinnesykdommersiver.a.moestue@ntnu.no 73551353 91111174 Olav Kyrres gate 9, MTFS*1.309
Bakgrunn og aktiviteter
Dr. Siver A. Moestue earned his PhD at the Norwegian University of Science and Technology (NTNU). He is currently a postdoctoral research fellow at the MR Centre, NTNU, on a personal research grant from the Norwegian Cancer Society. Trained a MSc. Pharm at the University of Oslo, he started his career as a preclinical researcher in GE Healthcare. Here, he was involved in development of molecularly targeted contrast agents for SPECT/PET, and development of the Sonazoid® microbubble. Currently, Dr. Moestue is investigating the use of MRI and MRS in cancer treatment and therapy monitoring, with special focus on metabolic biomarkers and drugs that inhibit cancer-specific metabolic abnormalities.
Vitenskapelig, faglig og kunstnerisk arbeid
Viser et utvalg av aktivitet. Se alle publikasjoner i databasen
Tidsskriftspublikasjoner
- (2015) MRI Reveals the in Vivo Cellular and Vascular Response to BEZ235 in Ovarian Cancer Xenografts with Different PI3-Kinase Pathway Activity. British Journal of Cancer. vol. 112 (3).
- (2015) In vivo 31P MRSI for metabolic profiling of human breast cancer xenografts. Journal of Magnetic Resonance Imaging. vol. 41 (3).
- (2014) Quantitative 31P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. Magnetic Resonance in Medicine. vol. 71 (6).
- (2014) Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Research. vol. 16 (1).
- (2013) Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Research. vol. 15 (1:R16).
- (2013) Low-molecular contrast agent DCE-MRI and DW-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. Journal of Magnetic Resonance Imaging. vol. 38 (5).
- (2012) Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. vol. 109 (38).
- (2011) MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR in Biomedicine. vol. 24 (6).
- (2011) HR MAS MR Spectroscopy in Metabolic Characterization of Cancer. Current Topics in Medicinal Chemistry. vol. 11 (1).
- (2010) Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer. vol. 10.
- (2009) Whole-body section fluorescence imaging - a novel method for tissue distribution studies of fluorescent substances. Contrast Media & Molecular Imaging. vol. 4 (2).